Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 92

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 92
---
 in future issuances, and the ability of U.S. shareholders to enforce judgments; •The registration of share capital increases or decreases in the Swiss commercial register may be delayed or blocked, and shareholder resolutions approving capital changes may be subject to challenge; •Our Common Shares are not listed on a Swiss exchange, and as a result, the Swiss takeover regime does not apply to us; •As a Swiss stock corporation, our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends, and otherwise manage ongoing capital needs; •Following the Merger, we may lose our foreign private issuer status, triggering U.S. domestic reporting requirements and increased compliance costs; •Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of NLS Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kadimastem; •The Merger is subject to the satisfaction or waiver of conditions that may not be satisfied or completed on a timely basis, if at all. Failure to consummate the Merger could adversely affect the future business and financial results of NLS; •NLS will have limited protection in the event that any of the representations and warranties made by Kadimastem ultimately proves to be inaccurate or incorrect; •Lawsuits may be commenced seeking to enjoin or prevent the Merger or seeking other relief which may delay or prevent the completion of the Merger and result in NLS or Kadimastem incurring substantial costs; and •The Merger may proceed despite material adverse changes, and if its benefits fall short of market expectations, NLS’s share price could decline. 19 These risks and other risks are discussed in greater detail under the section entitled “Risk Factors” in this proxy statement/prospectus. Nasdaq Capital Market Listing (see page 158) NLS has filed a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the issuance of NLS Common Shares in connection with the Merger or upon exercise of options or warrants or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares that will be assumed by NLS in connection with the Merger. If such application is accepted, NLS anticipates that its securities will be listed on the Nasdaq Capital Market following the Closing, and subject to approval of Proposals1,2,4,6,8, 13 and 14 in the NLS Meeting, will trade under NLS